PAD Profile : Etanercept - Juvenile idiopathic arthritis (adults)

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Etanercept - Juvenile idiopathic arthritis (adults)

PAD Profile : Etanercept - Juvenile idiopathic arthritis (adults) Important

Keywords :

JIA

Brand Names Include :

Enbrel, Benepali

Important Information :

Prescribe by brand. ICB commissioned in patients after 18 years of age

Traffic Light Status

Status 1 of 1.

Status :

Red

Formulations :

Not Specified

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

ICB

BlueTeq

NICE

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Canakinumab

Other Indications

Additional Documents

Type

Document

Review Date

Policy Statement

Etanercept biosimilar all CCG-commissioned indications - Policy Statement APC 432-2019 - August 2019.pdf

01 August 2022

Information

Biologics in adults with Juvenile Idiopathic Arthritis - BSPAR Position statement

Committee Recommendations

Date

Committee Name

Narrative

08 July 2019

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

31 July 2013

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The network discussed the BSPAR/BSR position statement noting that the purpose of the recommendations is due to the funding of biologics in children with JIA sits with NHS England but transfers to CCGs when the pts reach 18 years of age. It notes that JIA will often continue to have active disease (or sequelae from previous active disease) well into adult life and it is distinct from other inflammatory conditions. In order to facilitate care of patients with JIA persisting into adult life the statement recommends continuation of biologic treatment into adulthood with processes in place to ensure ongoing funding.

01 April 2013

Not Set

Etanercept for Juvenile idiopathic arthritis for children under 18 years of age will be funded by NHS England from 1st April 2013

Associated BNF Codes

10. Musculoskeletal and Joint Diseases

10.01.03. Rheumatic disease suppressant drugs